Clinuvel (CUV) set up for the next 200-350% run-up!
Chart pattern:
Since 2014 a regular chart-pattern can be observed in the Clinuvel (
CUV
) chart. After one year of a strong run-up (mostly starting in late February), the stock reaches a local peak (around Sept-Nov) and starts a correction (around -35% to -50%), followed by a longer sideways consolidation. Then the year after late Feb the next run-up starts. After the FDA approval in October 2019 the stock peaked, followed again by a strong and long correction and consolidation.
Currently, a new upmove started end of February 2021, bringing the stock from its recent correction low already up by 40% (20 AUD to 28 AUD).
Assuming the regluar pattern repeats, the new upmove has already started end of February and should bring the stock up to 60-86 AUD (200-330%) by autumn 2021.
Fundamental support of the coming run-up
Clinuvel is an innovative Biotech-Company, based in Melbourne Australia (ASX listed) and the world leader in Melanocortin-Hormones. Clinuvel offers the product "Scenesse" (Afamelanotide), which is approved in Europe since 2014, in USA since 2019 and in Australia and Israel since 2020. The company has no debts and is highly profitable.
There are several fundamental accelerators and good news to support a coming up-move:
- Continues expansion of the product in Europe (more and more countries are approved and reimbursed)
- Massive revenue growth expected in the USA, as the infrastructur for the distribution of Scenesse has been established now
- New Marketing and brand building initiatives
- New studies in place for label extension of the product
-> Vitiligo Phase 3 program to be started soon (Clinuvel is in final alignment with the FDA) (billon dollar market)
-> Ischemic stroke program: First study to be started shortly (billion dollar market)
-> XP study to proof DNA repair capabilities of Scenesse
-> Launch of OTC cosmetic products for mass market, with active ingredients for skin tanning (billion dollar market)
Overall, the management of the company is highly bullish to reach the set goals.
Since 2014 a regular chart-pattern can be observed in the Clinuvel (
CUV
) chart. After one year of a strong run-up (mostly starting in late February), the stock reaches a local peak (around Sept-Nov) and starts a correction (around -35% to -50%), followed by a longer sideways consolidation. Then the year after late Feb the next run-up starts. After the FDA approval in October 2019 the stock peaked, followed again by a strong and long correction and consolidation. Currently, a new upmove started end of February 2021, bringing the stock from its recent correction low already up by 40% (20 AUD to 28 AUD).
Assuming the regluar pattern repeats, the new upmove has already started end of February and should bring the stock up to 60-86 AUD (200-330%) by autumn 2021.
Fundamental support of the coming run-up
Clinuvel is an innovative Biotech-Company, based in Melbourne Australia (ASX listed) and the world leader in Melanocortin-Hormones. Clinuvel offers the product "Scenesse" (Afamelanotide), which is approved in Europe since 2014, in USA since 2019 and in Australia and Israel since 2020. The company has no debts and is highly profitable.
There are several fundamental accelerators and good news to support a coming up-move:
- Continues expansion of the product in Europe (more and more countries are approved and reimbursed)
- Massive revenue growth expected in the USA, as the infrastructur for the distribution of Scenesse has been established now
- New Marketing and brand building initiatives
- New studies in place for label extension of the product
-> Vitiligo Phase 3 program to be started soon (Clinuvel is in final alignment with the FDA) (billon dollar market)
-> Ischemic stroke program: First study to be started shortly (billion dollar market)
-> XP study to proof DNA repair capabilities of Scenesse
-> Launch of OTC cosmetic products for mass market, with active ingredients for skin tanning (billion dollar market)
Overall, the management of the company is highly bullish to reach the set goals.